1. From the Division of Biopharmaceutics (N.H., M.V.E., T.J.C.V.B.), Leiden/Amsterdam Center for Drug Research, Sylvius Laboratories, Leiden University, Leiden, the Netherlands; the Department of Vascular Biology (P.H.E.G.), SmithKline Beecham Research and Development, Harlow, Essex, UK; and the Department of Pediatric Oncology (P.M.H.), St. Radboud University Hospital, Nijmegen, the Netherlands.